摘要
恶性肿瘤常见的代谢并发症是高钙血症,又称恶性肿瘤高钙血症(HCM),有着较高的发病率和死亡率。2023年,美国骨矿盐研究学会和欧洲内分泌学会发布了《成人恶性肿瘤高钙血症的治疗:内分泌学会临床实践指南》,针对成人HCM、难治性和复发性高钙血症、骨化三醇相关高钙血症以及成人甲状旁腺癌引起的高钙血症相关重要临床问题提出了建议。本文对此作一介绍并对我国相关疾病的处理提出一些建议。
Hypercalcemia,a common metabolic complication of malignancies,often referred to as hypercalcemia of malignancy(HCM),is associated with a high incidence and mortality rate.In 2023,the American Society for Bone and Mineral Research and the European Society of Endocrinology released the Treatment of Hypercalcemia of Malignancy in Adults:An Endocrine Society Clinical Practice Guideline.This guideline aimed to address key clinical issues related to adult HCM,refractory and recurrent hypercalcemia,hypercalcemia associated with calcitriol,and hypercalcemia caused by adult parathyroid cancer.This article provides an overview of this guideline and offers some suggestions for managing related conditions in China.
作者
杨毓莹
朱旻婷
孙立昊
刘建民
Yang Yuying;Zhu Minting;Sun Lihao;Liu Jianmin(Department of Endocrine and Metabolic Diseases,Shanghai Institute of Endocrine and Metabolic Diseases,Shanghai National Clinical Research Center for Metabolic Diseases,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of General Practice,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2023年第10期821-825,共5页
Chinese Journal of Endocrinology and Metabolism
关键词
高钙血症
恶性肿瘤
治疗
Hypercalcemia
Malignant tumor
Treatment
